The Association of Gut Microbiota With COVID 19 Infection in Children
NCT ID: NCT05303155
Last Updated: 2023-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
40 participants
OBSERVATIONAL
2022-04-14
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
NCT05150834
Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts
NCT04980560
FMT for Post-acute COVID-19 Syndrome
NCT05556733
COVID-19 and Intestinal Microbiota in Children
NCT06503887
SARS-CoV-2 in Stools Compared to Respiratory Viral Strains.
NCT05567419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with COVID 19
Pediatric patient infected by COVID 19
16S rRNA sequencing
Fecal microbiome analysis using 16S rRNA sequencing
Pediatric patient without infection of COVID 19
Pediatric patient without infection of COVID 19
16S rRNA sequencing
Fecal microbiome analysis using 16S rRNA sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
16S rRNA sequencing
Fecal microbiome analysis using 16S rRNA sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* malignancy
* immunologic disease
3 Months
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hallym University Kangnam Sacred Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ky Young Cho
M.D., Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
KY YOUNG CHO, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hallym University Kangnam Sacred Heart Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hallym University Kangnam Sacred Heart Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Covid 19 and Gut Microbiota
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.